Hims & Hers Health, Inc. (BMV:HIMS)
Mexico · Delayed Price · Currency is MXN | Market Cap | 110.03B -61.1% |
| Revenue (ttm) | 42.72B +32.8% |
| Net Income | -238.59M |
| EPS | -1.05 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 24.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,937 |
| Open | 491.47 |
| Previous Close | 481.08 |
| Day's Range | 471.00 - 491.47 |
| 52-Week Range | 240.00 - 1,330.00 |
| Beta | 2.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About Hims & Hers Health
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial numbers in USD Financial StatementsNews
Hims & Hers Health Transcript: 2026 Evercore Global TMT Conference
Ambitious 2030 targets are set, driven by global expansion, specialty growth, and technology investments. Recent acquisitions and partnerships, especially with Eucalyptus and Novo Nordisk, accelerate international reach and deepen consumer engagement. AI and data are central to platform differentiation and operational efficiency.
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
BERLIN--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
SYDNEY--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest ...
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
TOKYO--(BUSINESS WIRE)--Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its form...
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company...
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on t...
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the...
Hims & Hers Health Slides: Investor presentation
Hims & Hers Health has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
HIMS Stock Crashed after Earnings. I Don’t Think the Growth Story Is Broken
The meltdown in Hims & Hers Health ($HIMS) stock has raised doubts about the company’s momentum. The post-earnings sell-off since its Q1 report came earlier this month shows the market…
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster drug Ozempic, through its ...
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada....
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible cus...
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% co...
Here’s Why Hims & Hers Stock Tumbled 9% Today, 5/18/26
Hims & Hers ($HIMS) shares fell 8.5% on Monday after the company said it plans to raise $300 million through a private offering of convertible senior notes due 2032. The…
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggre...
‘An Attractive Opportunity,’ Says Top Investor About Hims & Hers Stock
Well, that didn’t go as planned. Hims & Hers’ (NYSE:HIMS) Q1 2026 earnings report hit the market with a thud, and its share price has lost double digits in today’s…
Hims & Hers price target raised to $35 from $30 at Needham
Needham raised the firm’s price target on Hims & Hers (HIMS) to $35 from $30 and keeps a Buy rating on the shares. The company’s results came in below estimates…
Hims & Hers Drops After Earnings Miss & HIMS Options Trade
Marley Kayden breaks down Him & Hers (HIMS) after the company missed on both earnings and revenue. She explains how the end of the weight-loss drug shortage hurt their momentum, despite a rise in subs...
Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying
Hims & Hers Health ($HIMS) stock was down about 11% on Tuesday, as of writing, after the telehealth company reported a larger-than-anticipated loss for Q1 2026 and issued weak earnings…
Tuesday's Morning Movers: HIMS, ASTS & ONON Down on Earnings
Diane King Hall talks about notable earnings movers as markets open lower. Hims & Hers (HIMS) fell after a surprise loss as U.S. sales decline.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines c...
Hims & Hers tumbles 15% after earnings miss as GLP-1 transition weighs on results
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped...
Hims & Hers plummets 16% after first-quarter loss, weak earnings guidance
Digital health firm Hims & Hers' stock plummeted in premarket trading on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year.
Hims & Hers plunges after weight-loss pivot hits quarterly results
Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its weig...
Hims & Hers Health Swings to First-Quarter Loss as Expenses Rise
The telehealth platform posted a quarterly loss of $92.1 million, offsetting a 4% increase in revenue.